- Stocks
- Pharma & Healthcare
- Constronics Inf
Constronics Inf share price
NSE: CONSTRONICPharma & HealthcareEngineering & Construction
Constronics Inf at a glance
With a market capitalisation of ₹57 Cr, it ranks 3001st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Engineering & Construction.
Its return on equity was 8.1% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹7 Cr (−61.2% year on year) and net profit ₹0 Cr (−83.3%), on a consolidated basis. Promoters held 10.63% of the company as of 30 Jun 2026; 99.99% of promoter shares were pledged.
Key numbers
- Market cap
- ₹57 CrRank 3001 on NSE
- Price to book
- 2.27×FY25
- EPS (TTM)
- ₹2.26to Q4 FY26
- ROE
- 8.1%FY25
- ROCE
- 11.5%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 6.1%FY25
- Book value / share
- ₹30.90FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Constronics Inf quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹14 Cr | ₹16 Cr | ₹18 Cr | ₹13 Cr | ₹20 Cr | ₹9 Cr | ₹7 Cr |
| Revenue YoY | — | — | — | — | +345.5% | +42.5% | −43.0% | −61.2% |
| Net profit | −₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | — | — | — | — | — | +9.0% | −67.7% | −83.3% |
| Net margin | −2.1% | 8.8% | 6.0% | 5.5% | 7.8% | 6.8% | 3.4% | 2.4% |
| EPS | −₹0.05 | ₹0.98 | ₹0.76 | ₹0.81 | ₹0.80 | ₹1.07 | ₹0.25 | ₹0.14 |
Constronics Inf financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹51 Cr |
| Operating profit | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹4 Cr |
| Net profit | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹3 Cr |
| EPS (₹) | ₹0.13 | −₹0.11 | ₹0.24 | ₹0.08 | ₹0.99 | ₹2.64 |
| Cash from operations | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | −₹26 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹6 Cr | ₹0 Cr |
| Shareholders' equity | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹39 Cr |
Constronics Inf shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 10.63% | 10.63% | 10.63% | 10.63% | 10.63% | 10.63% |
| Non-institutions | 89.37% | 89.37% | 89.37% | 89.37% | 89.37% | 89.37% |
| Promoter shares pledged | — | — | — | — | 99.99% | 99.99% |
Constronics Inf vs peers
The listed Pharma & Healthcare companies nearest to Constronics Inf by market capitalisation.
Ask anything about Constronics Inf
Pivot answers on the live chart with evidence you can check, and tests strategies against CONSTRONIC's own history. Try: “Why has CONSTRONIC moved over the last three months?” · “Backtest a 50-day moving-average crossover on CONSTRONIC over five years” · “Compare CONSTRONIC with SAMRATPH on margins and valuation”
Frequently asked questions about Constronics Inf
What is the market cap of Constronics Inf?
Constronics Inf's market capitalisation is ₹57 Cr (₹57 Cr) at the 22 Oct 2026 close, ranking 3001st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Constronics Inf?
Return on equity was 8.1% in FY25 and return on capital employed was 11.5% in FY25 (standalone figures).
Is Constronics Inf a debt-free company?
Constronics Inf is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Constronics Inf's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Constronics Inf reported revenue of ₹7 Cr, −61.2% year on year, and net profit of ₹0 Cr, −83.3% year on year.
What is the shareholding pattern of Constronics Inf?
As of 30 Jun 2026: promoters 10.63%, non-institutions 89.37%. 99.99% of promoter shares were pledged.
Who are Constronics Inf's competitors?
The listed Pharma & Healthcare companies closest to Constronics Inf by market cap are Samrat Pharma, Royal Sense, Bacil Pharma, Veerhealth Care, Kabra Drugs and Bandaram Pharma.
Is Constronics Inf a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Constronics Inf's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONSTRONIC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text